Immune responses from early study of novel sarcoma vaccine

June 2, 2017 by Susan Keown, Fred Hutchinson Cancer Research Center

The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.

The findings give hope for a vaccine for sarcoma, called CMB305, an immunotherapy strategy that involves using an engineered virus to teach ' immune systems to recognize and kill tumor cells.

The findings will be presented by Dr. Seth Pollack, a physician-scientist at Fred Hutchinson Cancer Research Center, June 5 in a poster at the American Society of Clinical Oncology annual meeting in Chicago.

The poster presentation reinforces the results of an early-stage clinical trial led by Dr. Neeta Somaiah of MD Anderson Cancer Center and to be presented June 2 at the ASCO meeting. Pollack is a senior investigator on the trial.

In the poster presentation, Pollack—a physician-scientist who specializes in sarcoma—and his collaborators examined participants' immune responses before and after receiving the vaccine. They studied 62 patients enrolled in this trial or in an earlier trial that used only the virus component of the vaccine without the additional immune-boosters included in CMB305.

The data suggested that the vaccine was working as designed: In patients on both , Pollack and his collaborators found multiple signs of escalating immune responses to NY-ESO-1, a protein marker found almost exclusively in cancer cells, but not . An immune response directed at NY-ESO-1 will kill but leave healthy cells alone.

Patients' immune systems also started recognizing and responding to other cancer markers besides NY-ESO-1 after vaccination, too.

But across the board, Pollack's team observed the biggest boost in signs of anti-cancer immunity among patients vaccinated with the newer version of the vaccine, CMB305.

"My feeling is that [the additional component in the CMB305 vaccine] does help, because we definitely saw a better immune monitoring response," Pollack said.

In the June 2 ASCO presentation of the Phase 1 clinical trial results, Somaiah will report that in 16 of 25 participants with advanced, soft-tissue sarcoma, tumors stopped growing after the patients received injections of CMB305. Of these, about three-quarters had no disease progression by three months, 36 percent had no disease at six months and 83 percent of them were still alive after one year.

The results "compare favorably" to published data on several FDA-approved therapies for these cancers, Pollack said.

Patients received four injections of the engineered virus over three months, plus a series of injections of an immune-boosting formulation for a year. The two subtypes of sarcoma studied in this trial were myxoid/round cell liposarcoma and synovial .

"The results, so far, are exciting and show that the works; generates an and stabilizes tumors, and will definitely lead to additional studies," said Somaiah, who led the study. "Hopefully, if we design the studies right, we will have this as a treatment option in the near future."

One trial participant had a serious side effect (severe pain); the rest reported relatively minor side effects like soreness at the injection site that lasted one day.

"The lack of side effects makes the findings from the CMB305 trial especially noteworthy," Pollack said. "For most patients with these sarcomas, the most difficult symptoms they face throughout their illness are side effects from chemotherapy, which is a typical treatment for sarcomas."

The engineered virus in CMB305, which incorporates elements of multiple natural viruses, derives from discoveries made in the lab of Nobel Prize-winning scientist Dr. David Baltimore of CalTech. Baltimore and the Hutch's Dr. Larry Corey are among the scientific co-founders of Seattle's Immune Design, which owns CMB305 and sponsored this trial.

Explore further: Deploying an ancient defense to kill cancer

Related Stories

Deploying an ancient defense to kill cancer

April 3, 2017
A recent small trial in 15 cancer patients with advanced soft-tissue sarcomas aimed to find out whether an experimental drug based on a certain bacterial molecule could trigger an immune response to fight cancer.

First extensive immune profile of sarcomas shows some likely susceptible to immunotherapy

May 2, 2017
Sarcomas—cancers of the connective tissues like muscles, joints, fat and bone—come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic ...

Stem cell vaccine found to increase immune responses, inhibit tumors in animal models

May 10, 2017
Researchers at the University of Cincinnati (UC) have found that a cancer stem cell vaccine, engineered to express a pro-inflammatory protein called interleukin-15 (IL-15) and its receptor (IL-15Ralpha), caused T cell production ...

Triple immunotherapy for rare skin cancer shows promise in small, early-stage trial

May 30, 2017
Three out of four patients treated with an experimental combination of three different therapies for the rare skin cancer known as Merkel cell carcinoma are in complete remission following the treatment, according to study ...

Immunotherapy effective against some types of sarcoma

June 6, 2016
An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute (UPCI). Additional analyses of ...

Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy

April 10, 2014
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has ...

Recommended for you

Breast cancer genes a real risk for men, too

April 26, 2018
(HealthDay)—Few American men are screened for gene mutations that can greatly increase their risk of breast and other types of cancers, a new study reveals.

Metastatic cancer gorges on fructose in the liver

April 26, 2018
Biomedical engineers at Duke University have demonstrated that metastatic cancer cells can reprogram their metabolism to thrive in new organs. Specifically, the research shows that cells originating from colorectal cancer ...

Blood cancer precursor found in 9/11 firefighters

April 26, 2018
A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

Largest-ever study of thyroid cancer genetics finds new mutations, suggests immunotherapy

April 26, 2018
University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid ...

Molecular culprit behind virus-mediated chronic inflammation and cancers identified

April 26, 2018
Within cells infected by Kaposi sarcoma herpesvirus (KSHV), the human protein CADM1 interacts with viral proteins to promote chronic inflammation, which plays a major role in the development of cancers caused by KSHV. Richard ...

PARP-1 may be key to effectiveness of PARP inhibitors, and now researchers can image it

April 26, 2018
Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they've also proven they have a ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.